EA201990598A1 - Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы - Google Patents
Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способыInfo
- Publication number
- EA201990598A1 EA201990598A1 EA201990598A EA201990598A EA201990598A1 EA 201990598 A1 EA201990598 A1 EA 201990598A1 EA 201990598 A EA201990598 A EA 201990598A EA 201990598 A EA201990598 A EA 201990598A EA 201990598 A1 EA201990598 A1 EA 201990598A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- masp
- kits
- highly concentrated
- antibodies
- methods
- Prior art date
Links
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title abstract 3
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к стабильным высококонцентрированным низковязким препаратам ингибирующих MASP-2 антител, наборам, включающим препараты, и терапевтическим способам применения препаратов и наборов для ингибирования неблагоприятных эффектов зависимой от MASP-2 активации комплемента.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382156P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/049415 WO2018045054A1 (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990598A1 true EA201990598A1 (ru) | 2019-07-31 |
Family
ID=61301617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990598A EA201990598A1 (ru) | 2016-08-31 | 2017-08-30 | Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US11628217B2 (ru) |
| EP (2) | EP4438060A3 (ru) |
| JP (2) | JP6864747B2 (ru) |
| KR (2) | KR20190043161A (ru) |
| CN (3) | CN116327695A (ru) |
| AR (1) | AR109494A1 (ru) |
| AU (2) | AU2017321605B2 (ru) |
| CA (1) | CA3035252C (ru) |
| CL (1) | CL2019000508A1 (ru) |
| CO (1) | CO2019002239A2 (ru) |
| CR (1) | CR20190150A (ru) |
| CU (1) | CU20190015A7 (ru) |
| DK (1) | DK3506886T3 (ru) |
| EA (1) | EA201990598A1 (ru) |
| EC (1) | ECSP19021312A (ru) |
| ES (1) | ES2986902T3 (ru) |
| FI (1) | FI3506886T3 (ru) |
| GE (1) | GEP20217252B (ru) |
| HR (1) | HRP20241131T1 (ru) |
| HU (1) | HUE068084T2 (ru) |
| IL (1) | IL265071B2 (ru) |
| JO (1) | JOP20170170B1 (ru) |
| LT (1) | LT3506886T (ru) |
| MA (1) | MA46109A (ru) |
| MX (2) | MX2019002338A (ru) |
| MY (1) | MY189411A (ru) |
| PE (1) | PE20190469A1 (ru) |
| PH (1) | PH12019500365A1 (ru) |
| PL (1) | PL3506886T3 (ru) |
| PT (1) | PT3506886T (ru) |
| RS (1) | RS65845B1 (ru) |
| SG (2) | SG10202100697PA (ru) |
| SI (1) | SI3506886T1 (ru) |
| SM (1) | SMT202400333T1 (ru) |
| TW (2) | TWI719245B (ru) |
| UA (1) | UA122733C2 (ru) |
| UY (1) | UY37391A (ru) |
| WO (1) | WO2018045054A1 (ru) |
| ZA (1) | ZA201901891B (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202001580SA (en) | 2016-01-05 | 2020-04-29 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| JP2020531523A (ja) * | 2017-08-25 | 2020-11-05 | オメロス コーポレーション | 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法 |
| IL311042A (en) | 2018-05-29 | 2024-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2021013689A1 (en) * | 2019-07-19 | 2021-01-28 | Ichnos Sciences SA | Lyophilized antibody formulation |
| MX2022006334A (es) * | 2019-11-26 | 2022-06-22 | Omeros Corp | Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas. |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| AU2020395306B2 (en) | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| AU2020397894B2 (en) | 2019-12-04 | 2025-02-20 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| CA3190474A1 (en) | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| WO2022087610A1 (en) * | 2020-10-22 | 2022-04-28 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| BR112023025596A2 (pt) * | 2021-06-08 | 2024-02-27 | Jiangxi Jemincare Group Co Ltd | Anticorpo anti-masp-2 e uso do mesmo |
| AU2022405100A1 (en) | 2021-12-10 | 2024-07-25 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| US20230416406A1 (en) * | 2022-03-10 | 2023-12-28 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| TW202440159A (zh) * | 2022-12-29 | 2024-10-16 | 大陸商蘇州創勝醫藥集團有限公司 | 含有治療性抗體的藥物製劑及其用途 |
| US12216123B2 (en) | 2023-04-25 | 2025-02-04 | Nuvance Health | Extracellular vesicle derived MASP-2 directed cancer treatment methods |
| WO2024226573A2 (en) * | 2023-04-25 | 2024-10-31 | Nuvance Health | Masp-2 directed cancer treatment methods |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| US20250073310A1 (en) * | 2023-09-05 | 2025-03-06 | E-Star Biotech, LLC | Formulations of MANP and Uses Thereof |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2006330858A1 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| SI2488203T1 (sl) | 2009-10-16 | 2017-07-31 | Omeros Corporation | Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA3237802A1 (en) | 2011-04-08 | 2012-10-11 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| KR102024016B1 (ko) * | 2011-05-04 | 2019-11-04 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| RU2709351C2 (ru) | 2012-06-18 | 2019-12-17 | Омерос Корпорейшн | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
| WO2014141149A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
| AU2014337047B2 (en) | 2013-10-17 | 2020-03-12 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2016034648A1 (en) * | 2014-09-03 | 2016-03-10 | Medimmune Limited | Stable anti-il-4r-alpha antibody formulation |
| EP3240571A4 (en) | 2014-12-31 | 2018-06-13 | NovelMed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| MD4685C1 (ru) | 2015-11-09 | 2020-12-31 | Omeros Corporation | Метод лечения состояний, связанных с MASP-2-зависимой активацией комплемента |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| SG10202001580SA (en) | 2016-01-05 | 2020-04-29 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| CN109152834A (zh) | 2016-03-31 | 2019-01-04 | 奥默罗斯公司 | 抑制有需要的受试者的血管发生的方法 |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-08-28 JO JOP/2017/0170A patent/JOP20170170B1/ar active
- 2017-08-29 TW TW106129287A patent/TWI719245B/zh active
- 2017-08-29 TW TW108111015A patent/TWI730310B/zh active
- 2017-08-30 EA EA201990598A patent/EA201990598A1/ru unknown
- 2017-08-30 IL IL265071A patent/IL265071B2/en unknown
- 2017-08-30 EP EP24160975.9A patent/EP4438060A3/en active Pending
- 2017-08-30 CN CN202210971401.6A patent/CN116327695A/zh active Pending
- 2017-08-30 PE PE2019000408A patent/PE20190469A1/es unknown
- 2017-08-30 AU AU2017321605A patent/AU2017321605B2/en active Active
- 2017-08-30 PL PL17847485.4T patent/PL3506886T3/pl unknown
- 2017-08-30 ES ES17847485T patent/ES2986902T3/es active Active
- 2017-08-30 SG SG10202100697PA patent/SG10202100697PA/en unknown
- 2017-08-30 MY MYPI2019000424A patent/MY189411A/en unknown
- 2017-08-30 KR KR1020197008678A patent/KR20190043161A/ko not_active Ceased
- 2017-08-30 SM SM20240333T patent/SMT202400333T1/it unknown
- 2017-08-30 US US15/691,266 patent/US11628217B2/en active Active
- 2017-08-30 UA UAA201903034A patent/UA122733C2/uk unknown
- 2017-08-30 LT LTEPPCT/US2017/049415T patent/LT3506886T/lt unknown
- 2017-08-30 KR KR1020217035424A patent/KR102444154B1/ko active Active
- 2017-08-30 GE GEAP201715038A patent/GEP20217252B/en unknown
- 2017-08-30 FI FIEP17847485.4T patent/FI3506886T3/fi active
- 2017-08-30 CN CN202210971376.1A patent/CN116327917A/zh active Pending
- 2017-08-30 CA CA3035252A patent/CA3035252C/en active Active
- 2017-08-30 PT PT178474854T patent/PT3506886T/pt unknown
- 2017-08-30 SG SG11201901444PA patent/SG11201901444PA/en unknown
- 2017-08-30 MA MA046109A patent/MA46109A/fr unknown
- 2017-08-30 HR HRP20241131TT patent/HRP20241131T1/hr unknown
- 2017-08-30 SI SI201731539T patent/SI3506886T1/sl unknown
- 2017-08-30 WO PCT/US2017/049415 patent/WO2018045054A1/en active IP Right Grant
- 2017-08-30 CU CU2019000015A patent/CU20190015A7/es unknown
- 2017-08-30 HU HUE17847485A patent/HUE068084T2/hu unknown
- 2017-08-30 DK DK17847485.4T patent/DK3506886T3/da active
- 2017-08-30 JP JP2019531596A patent/JP6864747B2/ja active Active
- 2017-08-30 EP EP17847485.4A patent/EP3506886B1/en active Active
- 2017-08-30 CN CN201780051640.7A patent/CN109890367B/zh active Active
- 2017-08-30 CR CR20190150A patent/CR20190150A/es unknown
- 2017-08-30 RS RS20240925A patent/RS65845B1/sr unknown
- 2017-08-30 MX MX2019002338A patent/MX2019002338A/es unknown
- 2017-08-31 UY UY0001037391A patent/UY37391A/es active IP Right Grant
- 2017-08-31 AR ARP170102432A patent/AR109494A1/es not_active Application Discontinuation
-
2019
- 2019-02-20 PH PH12019500365A patent/PH12019500365A1/en unknown
- 2019-02-26 CL CL2019000508A patent/CL2019000508A1/es unknown
- 2019-02-26 MX MX2023014120A patent/MX2023014120A/es unknown
- 2019-03-11 CO CONC2019/0002239A patent/CO2019002239A2/es unknown
- 2019-03-27 EC ECSENADI201921312A patent/ECSP19021312A/es unknown
- 2019-03-27 ZA ZA2019/01891A patent/ZA201901891B/en unknown
-
2020
- 2020-11-24 AU AU2020277135A patent/AU2020277135B2/en active Active
-
2021
- 2021-04-02 JP JP2021063245A patent/JP7197623B2/ja active Active
-
2023
- 2023-02-28 US US18/176,155 patent/US20230226178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990598A1 (ru) | Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы | |
| MX2023015185A (es) | Degradadores de proteinas y usos de los mismos. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2020013881A (es) | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. | |
| EA202091898A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| MX383880B (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201691978A1 (ru) | Соединения в качестве модуляторов ror гамма | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
| MX392259B (es) | ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение |